Literature DB >> 2372619

Effectiveness and hazards of case finding for a high cholesterol concentration.

S Kinlay1, R F Heller.   

Abstract

OBJECTIVE: To see whether adults with high blood cholesterol concentrations (greater than 6.5 mmol/l) detected by case finding return to their doctor, receive appropriate advice, and report changes in their diet and whether adults found not to have high cholesterol concentrations on case finding are discouraged from changing their diet.
DESIGN: Follow up study.
SETTING: Seven general practices in the lower Hunter region of Australia. PARTICIPANTS: 600 Men and women aged 25-65 who had their blood cholesterol concentrations measured three to four months earlier while attending their general practitioner. Analysis conducted on 552 (92%) who returned follow up postal questionnaires.
MEASUREMENTS AND MAIN RESULTS: Of the 125 subjects found to have blood cholesterol concentrations greater than 6.5 mmol/l, 102 (82%) returned to their doctor and 83 of these recalled receiving dietary advice. 93 (75%) Subjects with high concentrations reported changing their diet compared with 72 (46%) subjects with concentrations of greater than 5.5-6.5 mmol/l and 44 (17%) subjects with lower concentrations. Overall 333 (61%) of all respondents who answered reported not changing their diet, the most common reason (nearly half the sample; n = 266) being that their cholesterol concentration was "all right." Adults without high cholesterol concentrations who returned to their doctor were also significantly more likely to recall their doctor saying that they did not need to lower their concentrations (less than or equal to 5.5 mmol/l = 61%; greater than 5.5-6.5 mmol/l = 12%; greater than 6.5 mmol/l = 5%) and significantly less likely to recall receiving dietary advice (less than or equal to 5.5 mmol/l = 13%; greater than 5.5-6.5 mmol/l = 60%; greater than 6.5 mmol/l = 82%).
CONCLUSIONS: High risk strategies which require everyone to be tested for high cholesterol concentrations may interfere with population strategies designed to reduce everyone's dietary intake of fat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372619      PMCID: PMC1663079          DOI: 10.1136/bmj.300.6739.1545

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  7 in total

1.  Sick individuals and sick populations.

Authors:  G Rose
Journal:  Int J Epidemiol       Date:  1985-03       Impact factor: 7.196

2.  Effect of screening and referral on follow-up and treatment of high blood cholesterol levels.

Authors:  L Råstam; R V Luepker; P L Pirie
Journal:  Am J Prev Med       Date:  1988 Sep-Oct       Impact factor: 5.043

3.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

4.  Reducing the risks of coronary heart disease in individuals and in the population.

Authors:  B Lewis; J I Mann; M Mancini
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

5.  Selective screening for high cholesterol in Australian general practice: the Newcastle Cholesterol Prediction Study.

Authors:  S Kinlay; R F Heller
Journal:  J Gen Intern Med       Date:  1990 Jan-Feb       Impact factor: 5.128

6.  Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study.

Authors:  D R Jacobs; E Barrett-Connor
Journal:  Am J Epidemiol       Date:  1982-12       Impact factor: 4.897

7.  Population screening for cholesterol determination. A pilot study.

Authors:  E L Wynder; F Field; N J Haley
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

  7 in total
  12 in total

1.  Cholesterol and coronary heart disease: screening and treatment.

Authors:  S Ebrahim; G D Smith; C McCabe; N Payne; M Pickin; T A Sheldon; F Lampe; F Sampson; S Ward; G Wannamthee
Journal:  Qual Health Care       Date:  1998-12

2.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?

Authors:  I S Kristiansen; A E Eggen; D S Thelle
Journal:  BMJ       Date:  1991-05-11

3.  Cost effectiveness of lowering cholesterol. Study did not take account of confounders.

Authors:  A Haycox; S Barton; T Walley
Journal:  BMJ       Date:  1996-11-02

4.  Population screening for genetic susceptibility to disease.

Authors:  A Clarke
Journal:  BMJ       Date:  1995-07-01

Review 5.  Role of C-reactive protein when prescribing a statin.

Authors:  Scott Kinlay
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 6.  Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

Authors:  T van der Weijden; J A Knottnerus; A J Ament; H E Stoffers; R P Grol
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

7.  Randomised controlled trial of the effects of physical activity feedback on awareness and behaviour in UK adults: the FAB study protocol [ISRCTN92551397].

Authors:  Clare Watkinson; Esther M F van Sluijs; Stephen Sutton; Theresa Marteau; Simon J Griffin
Journal:  BMC Public Health       Date:  2010-03-18       Impact factor: 3.295

8.  Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines.

Authors:  W J McIsaac; C D Naylor; A Basinski
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

9.  Motivational effect of cholesterol measurement in general practice health checks.

Authors:  I Robertson; A Phillips; D Mant; M Thorogood; G Fowler; A Fuller; P Yudkin; M Woods
Journal:  Br J Gen Pract       Date:  1992-11       Impact factor: 5.386

10.  Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial.

Authors:  Charlotte A M Paddison; Helen C Eborall; Stephen Sutton; David P French; Joana Vasconcelos; A Toby Prevost; Ann-Louise Kinmonth; Simon J Griffin
Journal:  BMJ       Date:  2009-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.